logo
Plus   Neg
Share
Email

Amgen: FDA Approves Earlier Use Of Nplate To Treat Immune Thrombocytopenia

Amgen (AMGN) said the FDA has approved the Supplemental Biologics License Application (sBLA) for Nplate to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia. The updated indication expands treatment with Nplate to newly diagnosed and persistent adult immune thrombocytopenia patients who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

David Reese, executive vice president of Research and Development at Amgen, stated: "This approval will provide patients the opportunity to receive Nplate earlier in the course of their disease, potentially reducing their need for prolonged steroid use."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT
>